Market Place
Sourcing Support
Pfizer pulls sickle cell disease drug Oxbryta from global markets
26 Sep 2024 //
PRESS RELEASE
NHS to provide Pfizer’s Voxelotor to treat sickle cell disease
03 May 2024 //
PHARMACEUTICAL TECHNOLOGY
FDA Confirms Paragraph IV Patent Litigation for Voxelotor Tablets
26 Jan 2024 //
FDA
Global Blood Therapeutics` Oxbryta (voxelotor) Receives Approval in Europe
13 Jun 2023 //
EMA
Pfizer`s Oxbryta (Voxelotor) Approved In Europe
06 Jun 2023 //
EMA
EU officials taking closer look at Novartis` Adakveo after flop
30 Jan 2023 //
FIERCE PHARMA
MHRA grants marketing authorisation for Global Blood Therapeutics’s Oxbryta
26 Jul 2022 //
PHARMATIMES
MHRA Grants MAA for GBT`s Oxbryta (voxelotor) for Use in Hemolytic Anemia in SCD
26 Jul 2022 //
GLOBENEWSWIRE
GBT Initiates Expanded Access Program for Voxelotor in SCD
14 Jul 2022 //
GLOBENEWSWIRE
GBT Reports First Quarter 2022 Financial Results
04 May 2022 //
GLOBENEWSWIRE
GBT`s Biologic Oxbryta (Voxelotor) Receives Approval in Europe
17 Mar 2022 //
EMA
EMA Approves OXBRYTA in EU to Target the Cause of SCD
25 Feb 2022 //
PRNEWSWIRE
EAMS Scientific Opinion Awarded to Voxelotor for Haemolytic Anaemia Due to SCD
27 Jan 2022 //
GLOBENEWSWIRE
U.S. FDA Approves sNDA for Expanded Indication of Oxbryta®
17 Dec 2021 //
IRGBT
GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion
17 Dec 2021 //
GLOBENEWSWIRE
U.S. FDA Approves Supplemental New Drug Application for Expanded of Oxbryta
17 Dec 2021 //
GLOBENEWSWIRE
GBT Wins Prestigious Prix Galien USA Award for Oxbryta® (voxelotor)
01 Nov 2021 //
GLOBENEWSWIRE
FDA Accepts for Priority Review sNDA for Oxbryta for SCD in Children 4 to 11
07 Sep 2021 //
GLOBENEWSWIRE
GBT’s Voxelotor to Receive PIM Designation in the UK
14 Jun 2021 //
GLOBENEWSWIRE
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta®
08 Apr 2021 //
GLOBENEWSWIRE
With all the buzz in gene therapy, Sanofi offloads two small $11.6B buyout
17 Mar 2021 //
ENDPTS
GBT Initiates Expanded Access Protocol for Oxbryta® (voxelotor)
04 Feb 2021 //
GLOBENEWSWIRE
EMA begins review of GBT`s sickle cell treatment Oxbryta
29 Jan 2021 //
PHARMATIMES
EMA begins review of GBT`s sickle cell treatment Oxbryta
29 Jan 2021 //
PHARMATIMES
GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta®
07 Dec 2020 //
GLOBENEWSWIRE
GBT Receives Rare Impact Award for Innovation the (NORD)Oxbryta® (voxelotor)
12 Oct 2020 //
GLOBENEWSWIRE
GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta (voxelotor)
08 Sep 2020 //
GLOBENEWS WIRE
GBT Announces Plans to Seek Regulatory Approval for Oxbryta®
24 Jun 2020 //
GLOBENEWSWIRE
GBT Announces Plans to Seek Expanded Labeling for Oxbryta® (voxelotor)
08 Jun 2020 //
GLOBENEWSWIRE
GBT chief cites COVID-19 for `clear` Oxbryta launch slowdown
08 May 2020 //
FIERCE PHARMA
GBT looks to take a page from HIV playbook with Oxbryta launch
14 Feb 2020 //
FIERCE PHARMA
Two CEOs, two different therapies, and a fight to chase down sickle cell
17 Jan 2020 //
END PTS
Global Blood Therapeutics scores FDA nod for Oxbryta
27 Nov 2019 //
FIERCE PHARMA
Global Blood Therapeutics Prices a $200.0 Million Common Stock Public Offering
27 Jun 2019 //
BIOSPACE
GBT sickle cell trial hits endpoint ahead of NDA filing
18 Jun 2019 //
FIERCE BIOTECH
Global Blood Therapeutics Gets A Quick Advance Surprise By The FDA
06 Dec 2018 //
SEEKING ALPHA
Armed with Ph3 data, GBT convinces FDA to review SCD drug under acc pathway
03 Dec 2018 //
ENDPTS
